CV THERAPEUTICS INC·4

Apr 16, 4:57 PM ET

DAVIE JOSEPH MD PHD 4

4 · CV THERAPEUTICS INC · Filed Apr 16, 2009

Insider Transaction Report

Form 4
Period: 2009-04-14
Transactions
  • Exercise/Conversion

    Nonqualified Stock Option (right to buy)

    2009-04-14$11.26/sh2,500$28,1500 total
    Exercise: $8.74From: 2008-06-20Exp: 2018-05-20Common Stock (2,500 underlying)
Footnotes (1)
  • [F1]This option to purchase shares of the Issuer's stock, which provided that 8.33% of the shares subject to the option shall vest per month over the 12 month period following the May 20, 2008 date of grant, became 100% vested and exercisable due to a change in control of the Issuer effected through the tender offer by Apex Merger Sub, Inc. ("Apex"), a wholly owned subsidiary of Gilead Sciences, Inc. ("Gilead), effective as of April 14, 2009. The Issuer will make a cash payment of $21,150, representing the gross cash amount for the remaining shares subject to this option which became 100% vested and exercisable due to the change in control, to the Reporting Party.

Documents

1 file
  • 4
    rrd239894.xmlPrimary

    DAVIE APRIL 14, 2009 CASH PAYMENT FOR STOCK OPTION EXERCISE DUE TO CHANGE IN CONTROL